Current filters:


Popular Filters

8110 to 8134 of 8806 results

UK MHRA proposes safeguard for medicines supplies for patients


The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has proposed repeal of the part…

EuropeMarkets & MarketingPharmaceuticalRegulation

Drugmakers are using innovative partnerships to spur development, says Tufts CSDD


Responding to strong and growing pressure to reduce development times and increase the output of new…

LicensingNorth AmericaPharmaceuticalResearch

Global bio-pharma clinical leaders to call for industry transformation at 21st Annual Partnerships in Clinical Trials


Clinical development, outsourcing and operations decision makers from the world’s top bio-pharmaceutical…


Pres Obama orders FDA action to reduce Rx drug shortages in USA


in frequency and severity in recent years and adversely affecting patient care. A small number of drugs…

GenericsNorth AmericaPharmaceuticalPoliticsRegulation

UK NICE recommends Boehringer’s Pradaxa for stroke prevention


In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

NPS Pharma posts overall positive Gattex data, but shares plunge due to two deaths


Shares in USA-based NPS Pharmaceuticals (Nasdaq: NPSP) plummeted as much as 38% to $4.92 in morning trading…

Gastro-intestinalsGattexNPS PharmaceuticalsNycomedPharmaceuticalResearchRevestive

MS drugs push Biogen Idec 3rd-qtr 2011 net income 38% higher


US biotech company Biogen Idec (Nasdaq: BIIB) posted third-quarter 2011 financial results, showing that…

Biogen IdecBiotechnologyFinancial

Oxford BioMedica in glaucoma R&D accord with Mayo Clinic


UK-based Oxford BioMedica (LSE: OXB) has entered into an R&D collaboration with the USA’s Mayo Clinic…

BiotechnologyLicensingOphthalmicsOxford BioMedicaPharmaceuticalResearchSanofi

Expanding Norwegian cancer cluster adds new start-ups


In Norway, the Oslo Cancer Cluster represents a strong R&D environment dedicated to oncology. The true…


Australia’s GMiA completes Code review; comments on PBS cuts and vital role of pharma manufacturing


Martin Cross, chairman of Australia’s Generic Medicines Industry Association (GMiA) has warned that…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalPricingRegulation

Merck & Co posts strong 3rd-qtr 2011results as profit leaps 9.9% and sales rise 8%


US drugs giant Merck & Co (NYSE: MRK) post third-quarter 2011 financial results late Friday, showing…

FinancialMerck & CoPharmaceutical

Roche offers Germany a pay-for-performance deal on Avastin


In Germany’s tight market for new and existing drugs to gain reimbursement, Swiss drug major Roche…


Brazil pharma market driven by generic medicines


According to the Ministry of Health, the Brazilian pharmaceutical market has grown to $28 billion annually,…

GenericsMarkets & MarketingPharmaceuticalSouth America

Shire posts strong 3rd-qtr 2011 results, with sales beating expectations


The UK’s third largest drugmaker, Shire (LSE: SHP), reported third-quarter 2011 total revenues of…


Greece’s Pharma industry faced with most challenging environment in Europe


It is now beyond doubt that drugmakers in Greece - particularly domestic producers, primarily exposed…

EuropeMarkets & MarketingPharmaceutical

Regular aspirin intake halves hereditary cancer risk, scientists conclude


Scientists, including those from Queen's University in Belfast, Northern Ireland, have discovered that…


Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report


By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

8110 to 8134 of 8806 results

Back to top